肺泡表面活性物质阿尔法与贝拉克坦治疗新生儿呼吸窘迫综合征的回顾性成本分析
Poractant Alfa Versus Beractant for Neonatal Respiratory Distress Syndrome: A Retrospective Cost Analysis.
作者信息
Brown Sara, Hurren Jeff, Sartori Heidi
出版信息
J Pediatr Pharmacol Ther. 2018 Sep-Oct;23(5):367-371. doi: 10.5863/1551-6776-23.5.367.
OBJECTIVES
The objectives of this study were to determine the average medication cost per patient of poractant alfa and beractant, and to compare the outcomes of treatment with these agents.
METHODS
We conducted a retrospective, observational, cohort study of patients who received surfactant, before and after an institutional formulary change from beractant to poractant alfa. The primary outcome was the average medication cost per case. Secondary measures were clinical outcomes, including duration of respiratory support, length of hospital stay, and the occurrence of complications.
RESULTS
A total of 114 patients were enrolled; 38 were treated with poractant alfa and 76 patients were treated with beractant. Baseline characteristics were similar between groups. The average medication cost per patient was $1756.44 ± $1030.06 and $1329.78 ± $705.64 for poractant alfa and beractant, respectively (p = 0.011). Patients treated with poractant alfa had a shorter length of stay (45.0 ± 30.5 days) than patients treated with beractant (65.1 ± 37.1 days) (p = 0.010). Rates of pneumothoraces, pulmonary hemorrhage, necrotizing enterocolitis, intraventricular hemorrhage, and mortality did not differ significantly between groups.
CONCLUSIONS
We found an unanticipated increase in drug cost with poractant alfa compared to beractant.
目的
本研究的目的是确定接受猪肺磷脂和固尔苏治疗的每位患者的平均药物费用，并比较使用这些药物的治疗结果。
方法
我们对在机构处方从固尔苏更换为猪肺磷脂之前和之后接受表面活性剂治疗的患者进行了一项回顾性观察队列研究。主要结局是每例患者的平均药物费用。次要指标为临床结局，包括呼吸支持持续时间、住院时间和并发症的发生情况。
结果
共纳入114例患者；38例接受猪肺磷脂治疗，76例接受固尔苏治疗。两组间基线特征相似。猪肺磷脂和固尔苏治疗的每位患者平均药物费用分别为1756.44美元±1030.06美元和1329.78美元±705.64美元（p = 0.011）。接受猪肺磷脂治疗的患者住院时间（45.0±30.5天）比接受固尔苏治疗的患者（65.1±37.1天）短（p = 0.010）。两组间气胸、肺出血、坏死性小肠结肠炎、脑室内出血和死亡率无显著差异。
结论
我们发现，与固尔苏相比，猪肺磷脂的药物成本意外增加。
Zotero 插件